HYOU1
protein-codinghypoxia up-regulated 1, the group of Heat shock 70kDa proteins
Gene summary
The protein encoded by this gene belongs to the heat shock protein 70 family. This gene uses alternative transcription start sites. A cis-acting segment found in the 5' UTR is involved in stress-dependent induction, resulting in the accumulation of this protein in the endoplasmic reticulum (ER) under hypoxic conditions. The protein encoded by this gene is thought to play an important role in protein folding and secretion in the ER. Since suppression of the protein is associated with accelerated apoptosis, it is also suggested to have an important cytoprotective role in hypoxia-induced cellular perturbation. This protein has been shown to be up-regulated in tumors, especially in breast tumors, and thus it is associated with tumor invasiveness. This gene also has an alternative translation initiation site, resulting in a protein that lacks the N-terminal signal peptide. This signal peptide-lacking protein, which is only 3 amino acids shorter than the mature protein in the ER, is thought to have a housekeeping function in the cytosol. In rat, this protein localizes to both the ER by a carboxy-terminal peptide sequence and to mitochondria by an amino-terminal targeting signal. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2014]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~13.0 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0009305
Submitter: ClinGen
*HYOU1* (also known as *ORP150*, *HSP12A*, and Grp170) was first reported in relation to autosomal recessive granulocytopenia with immunoglobulin abnormality in 2017 (Haapaniemi et al., PMID: 27913302). Immunodeficiency-59 and hypoglycemia (IMD59) is an autosomal recessive primary immunologic disorder characterized by combined immunodeficiency and recurrent septic infections of the respiratory tract, skin, and mucous membranes, as well as disturbed glucose metabolism. Granulocyte, B-cell, and dendritic cell deficiency are present. Six missense variants reported in four probands in four publications (PMIDs: 27913302, 35549617, 35822684, 32888943) are included in this curation. The probands presented with frequent septic infections of the respiratory tract and skin, granulocytopenia, psychomotor deterioration, neutropenia, low B-cell count, normal CD4+ T cells, and normal CD8+ T cells among other phenotypes. The mechanism of pathogenicity is not clear. Other pathogenic or likely pathogenic variants reported in ClinVar are large copy number changes that include more genes than *HYOU1*. This gene-disease relationship is also known as immunodeficiency 59 and hypoglycemia (MONDO:0009305) which has been supported by experimental evidence (expression studies) (PMIDs:18094145, 35822684). *ORP150* plays an important role in protein folding and secretion in the ER, perhaps as a molecular chaperone in concert with other stress-induced genes referred to as glucose-regulated proteins (GRPs). GRPs are members of the stress-responsive superfamily of genes that also includes heat shock proteins (HSPs). GRPs and HSPs are essential for normal cellular function, and *ORP150* regulation may play a crucial role in coping with environmental stress. *HYOU1* is one of many genes that are associated with congenital neutropenia, disorders characterized by low neutrophil counts, susceptibility to infections, and viable developmental abnormalities. The hypogammaglobulinemia associated with *HYOU1* deficiency is however less common among congenital neutropenia disorders. Like many of the other congenital neutropenia genes, pathogenic variants in *HYOU1* are associated with a risk for leukemic transformation. Animal models (PMIDs: 10037731, 15223375, 11714735) of *ORP150* deficiency do not have signs of granulocytopenia or hypogammaglobulinemia but instead, exhibit neurodegenerative features. Neurodegeneration has not been described in patients with *HYOU1*-related granulocytopenia with immunoglobulin abnormality but most have died early in life so it remains unclear whether this could develop with age. In summary, there is limited evidence supporting the relationship between *HYOU1* and autosomal recessive granulocytopenia with immunoglobulin abnormality. This classification was approved by the ClinGen Primary Immune Regulatory Disorders GCEP on the meeting date January, 21, 2025 (SOP Version 11).
Inheritance Pattern: Unknown
Disease ID:MONDO:0009305
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0009305
Submitter: Ambry Genetics
Inheritance Pattern: AR
Disease ID:MONDO:0009305
Submitter: PanelApp Australia
Clinical Genomic Database (CGD)
Manifestation: Allergy/Immunology/Infectious; Endocrine
Intervention: Allergy/Immunology/Infectious; Endocrine
Rationale: The condition has been described as involving recurrent infection, and antiinfectious prophylaxis and early and aggressive treatment of infections may be beneficial; Abnormal gluocose metabolism (resulting in hypoglycemia) has been described, and awareness may allow prompt management
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to HYOU1 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_006389.5. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 48 | 152 | 6 | 206 | ||
| missense | 3 | 427 | 12 | 442 | ||
| nonsense | 4 | 4 | ||||
| start loss | 0 | |||||
| frameshift | 3 | 3 | ||||
| splice donor/acceptor (+/-2bp) | 7 | 7 | ||||
| Total | 3 | 0 | 489 | 164 | 6 | 662 |
Highest pathogenic variant AF is 6.86144e-7
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_006380.1 | 25 | MANE Select | |
| Ensembl | ENSP00000480150.1 | 25 | MANE Select | |
| RefSeq | NP_001124463.1 | 25 | Standard | |
| RefSeq | NP_001397970.1 | 25 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Protein processing in endoplasmic reticulum - Homo sapiens (human)
- Ibuprofen Action Pathway
- Phenytoin (Antiarrhythmic) Action Pathway
- Ibuprofen Metabolism Pathway
- Morphine Metabolism Pathway
Biological Process
- response to ischemia
- endoplasmic reticulum to Golgi vesicle-mediated transport
- receptor-mediated endocytosis
- response to endoplasmic reticulum stress
- IRE1-mediated unfolded protein response
Molecular Function
- ATP binding
- chaperone binding
Cellular Component
- extracellular region
- endoplasmic reticulum
- endoplasmic reticulum lumen
- smooth endoplasmic reticulum
- focal adhesion
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000404233
- Coding exons
- 25
- Length
- 13014
- Individuals with no LoFs
- 125726
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 22
- Defined
- 125748
- p
- 0.0000875
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.80 | 472 | 596 | 0.792 | 0.0000360 | 6538 |
| Missense (PolyPhen) | 96 | 182.65 | 0.52559 | 2059 | ||
| Synonymous | -0.486 | 237 | 228 | 1.04 | 0.0000135 | 1969 |
| Loss of Function | 5.49 | 11 | 54.9 | 0.200 | 0.00000303 | 608 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00031 | 0.00031 | rare |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0.000099 | 0.000099 | rare |
| East Asian | 0.00016 | 0.00016 | rare |
| Finnish | 0.00022 | 0.00018 | rare |
| European (Non-Finnish) | 0.000035 | 0.000035 | rare |
| South Asian | 0.00013 | 0.00013 | rare |
| Other | 0.00016 | 0.00016 | rare |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Has a pivotal role in cytoprotective cellular mechanisms triggered by oxygen deprivation. May play a role as a molecular chaperone and participate in protein folding. {ECO:0000269|PubMed:10037731}.;
Recessive Scores
- pRec
- 0.180
Intolerance Scores
- LoFtool
- 0.406
- RVIS EVS
- -1.84
- RVIS percentile EVS
- 2.08
Essentials
- Essential (CRISPR)
- E
- Essential (CRISPR2)
- E
- Essential (gene trap)
- N
- Indispensability pred.
- N
- Indispensability score
- 0.498
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |